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SUMMARY 
The availability of misoprostol is a key part of 
improving maternal health in low- and middle-
income countries. In Senegal, where the drug 
is not widely available, pharmacies are one of 
the few places women can access it.  
 
STEP UP conducted a study to understand 
misoprostol knowledge and provision in these 
pharmacies. Stakeholder uptake of the results 
brought about several important achievements: 
 Expansion of MSI’s regional programme 
strategy to include training of both 
pharmacists and health care providers; 
 Provision of information on the legal status 
and correct regimen of Misoclear during 
pharmaceutical detailer visits, to improve 
pharmacists’ knowledge of and confidence 
to purchase and sell misoprostol.  
 A commitment from the Ministry of Health 
to train pharmacists on misoprostol was 
secured. 
  
STEP UP generates 
policy-relevant research 
to promote an evidence-
based approach for 
improving access to  
family planning and  
safe abortion.  
 
We work in Bangladesh, 
northern India, Ghana, 
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FROM EVIDENCE TO IMPACT: A look at how STEP UP 
research was used to impact policies and programmes 
The goal of family planning and reproductive health operations research is to generate 
evidence that helps policies and programmes maximize access to and quality of services 
for women and their families. Yet the crucial step of ensuring the utilization of that 
evidence often receives inconsistent or inadequate attention. There is relatively little 
monitoring and reporting on whether and to what effect project results are utilized, or on 
the nature, process, and efficacy of the strategies employed to achieve this.  
The goal of this case study is to document an activity of the STEP UP research 
programme consortium which resulted in successful evidence utilization. This is to both 
demonstrate the positive impact STEP UP is having on family planning and reproductive 
health policies, as well as to document the process by which this was achieved so as to 
inform future research of successful strategies and lessons learned. 
  
INTRODUCTION 
Misoprostol is scarcely available in Senegal, despite being 
essential for the management of postpartum hemorrhage 
(PPH) and post-abortion care (PAC) and included on the 
List of Essential Medicines (EML) of both the World Health 
Organization (WHO) and the Senegalese Ministry of 
Health (MoH).  
Misoprostol in Senegal can only be obtained via 
prescription, and is supplied almost exclusively by private 
sector facilities. It is not procured by the MoH for the 
public sector, with only 1% of public sector health 
providers reporting its use in 2013. 
 
THE PROJECT 
In 2013, Marie Stopes International (MSI) and the 
Population Council conducted a study on misoprostol 
knowledge and distribution practices amongst private 
pharmacies in Dakar. The study is part of the work 
undertaken by the “Strengthening Evidence for 
Programming on Unintended Pregnancy (STEP UP)” 
research consortium, with funding from DFID. 
 
The aim of the study was to inform strategies to improve 
misoprostol provision in an effort to reduce maternal 
mortality, by gaining an understanding of the knowledge, 
attitudes and practices (KAP) of misoprostol provision 
amongst 110 private sector pharmacists in Dakar. The 
study took place in the context of governmental targets to 
reduce maternal mortality from 392 in 2010/11 to 127 
deaths per 100,000 live births by the end of 2015.  
 
KEY STUDY RESULTS 
 Only 35% of pharmacists sold misoprostol, of which 
the majority (70%) reported selling it only for 
duodenal or gastric ulcers, rather than for 
gynaecological conditions such as postpartum 
haemorrhage (PPH) and post abortion care (PAC). 
 Less than 5% of pharmacists knew misoprostol could 
be used for the management of PPH, none reported 
selling it for this purpose, and none knew the correct 
dosage. 
 Only 13% of pharmacists knew misoprostol was 
registered for PAC; 3.7% reported selling it for this 
indication, but only 0.5% of all pharmacists knew the 
correct dosage. 
 51% of pharmacists reported not being confident 
providing misoprostol to clients. 
 38% of pharmacists knew that misoprostol can be 
used to induce abortion.  
 Only one respondent reported having sold 
misoprostol to a client without a prescription; 
 48% of those not selling misoprostol expressed a 
desire to do so. 
 42% of those not stocking misoprostol stated that the 
reason was that they did not want to sell abortifacient 
products.  
 
Fig. 1: Pharmacist reasons for not selling Misoprostol 
 
 
MAKING AN IMPACT 
Influencing policies and programming 
improvements 
This section presents how the evidence from the study 
was used, and what impact it had on access to 
misoprostol in Senegal.   
 
Expansion of MSI’s programme strategy to include 
training of health care providers 
The low sales of misoprostol for gynecological 
indications reported by pharmacists were in part due to a 
lack of prescriptions issued by health care providers, 
such as doctors, nurse and midwives. As a result of the 
study, MSI broadened its strategy to include training of 
public providers, having previously focused on capacity 
building amongst pharmacists alone to increase access 
to misoprostol.  
 
MSI Senegal collaborated with the Ministry of Health and 
Gynuity Health Projects to train 1020 public sector service 
providers in 35 districts on the uses of misoprostol by 
January 2015, with plans to train another 1200 by late 
2015. This strategy of training health care providers later 
became part of MSI’s regional approach to scaling up 






































Improving communication with pharmacists to build 
confidence to sell misoprostol  
Low knowledge of misoprostol registration status and 
regimen for gynaecological indications limited 
pharmacists’ confidence in procuring and selling the 
product. In response, the pharmaceutical detailers 
responsible for marketing Misoclear (MSI’s branded 
product) to pharmacists were re-trained on its use and 
their remit expanded, enabling them to share information 
on the legal status and correct provision of Misoclear. 
These topics are now covered during detailing visits with 
the aim of imparting knowledge and improving confidence 
to purchase and sell misoprostol.  
The impact of this strategy is evidenced by the increase in 
the number of pharmacists who stock Misoclear from 253 
in December 2014 to 415 pharmacists in June 2015.¹   
 
Commitment by the Ministry of Health to train 
pharmacists on misoprostol 
Two dissemination events were held, co-hosted with the 
Directorate of Reproductive Health and Child Survival 
(DSRSE). These events provided opportunities for MSI 
Senegal and the Population Council to highlight the 
importance of misoprostol and its contribution to reducing 
maternal mortality in Senegal to stakeholders and the 
media. At the second dissemination event, the MoH 
committed to training pharmacists on all essential 
medicines, including misoprostol. The events were a 
result of the strong relationship between the study team 
and the DSRSE.  
 
Who will benefit? 
Through these improvements in service access, quality, 
and political and programmatic support, there is the 
potential that benefits will be seen at a number of levels: 
 Individuals: Fewer women may suffer or die of 
treatable maternal health conditions like PPH and 
PAC by using misoprostol. Not only will they be able 
to obtain this lifesaving drug from more locations, but 
the improved skills of public sector providers and 
pharmacists may result in better quality services. 
 Communities: Women play central roles in family 
and community life. By improving access to 
misoprostol, preventable deaths and diseases may 
be avoided, helping to keep communities stable and 
healthy. 
 National goals: Senegal’s goal of reducing maternal 
mortality from 392 in 2010/11 to 127 deaths per 
100,000 live births by the end of 2015 is made more 
attainable by this progress towards making 
misoprostol more available to women who need it. 
 
HOW WAS IMPACT ACHIEVED? 
SOME KEY LESSONS LEARNED 
 
Strong relationships with 
policymakers  
The two dissemination events that contributed to the 
Ministry of Health’s commitment to train pharmacists 
on misoprostol were the result of the strong 
relationship between the study team and the DSRSE. 
Not only did the events enable widespread 
dissemination of information on misoprostol’s role in 
reducing maternal mortality, but they were also co-
hosted with the DSRSE; this helped to promote the 
Ministry’s ownership of the study’s recommendations. 
The director of the DSRSE is also a supporter of 
improving women’s access to evidence-based family 
planning and reproductive health services, and his 
commitment enabled further support and utilization of 
the study’s findings. 
 
Support of the Order of Pharmacists  
The involvement of the Order of Pharmacists from 
project inception was essential for building ties with the 
pharmacists involved in the study. The Order provided 
the list of pharmacies in Dakar, and prior to data 
collection they sent informational letters to the 
pharmacies to introduce them to the project. This 
enabled early links with pharmacists, and may have 
bolstered their engagement with the research team as 
well as their receptiveness to the more accurate 
information shared by the re-trained pharmaceutical 
detailers who market and explain the legal status and 




1 - MSI Senegal only has information related to Misoclear and not other brands 
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CONCLUSION 
By evidencing barriers to misoprostol access and 
provision, this study raised awareness for a little 
understood public health issue that continues to 
contribute to maternal mortality in Senegal.  
 
The MoH’s commitment to training public providers and 
pharmacists on all products on the essential medicines 
list is a promising step towards bettering the health of 
women in Senegal. At the time of writing, the pharmacy 
training had not yet been brought to fruition.  
 
Further research is needed to investigate the 
knowledge, attitudes and practices of service providers 
responsible for prescribing misoprostol, as well as the 
impact that training such providers will have on use of 
the product.  
 
MSI Senegal continues to work to build the capacity of 
healthcare providers in the public sector, while both 
MSI Senegal and the Population Council remain 
committed to supporting the MoH to reduce levels of 
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By evidencing barriers to misoprostol 
access and provision, this study raised 
awareness for a little-understood public 
health issue that continues to 
contribute to maternal mortality in 
Senegal. 
